Company page

Prostatype Genomics Ab

Prostatype Genomics Ab, trading under the ticker PROGEN, is a public company based in Sweden with a market capitalization of approximately 3 million USD. The company focuses on genomics and personalized medicine, aiming to improve prostate cancer diagnosis and treatment. Its innovative approach leverages genetic insights to enhance patient outcomes in oncology.